Loading clinical trials...
Loading clinical trials...
Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bausch Health Americas, Inc.
NCT06483737 · Overt Hepatic Encephalopathy
NCT04058327 · Hepatic Encephalopathy, Minimal Hepatic Encephalopathy, and more
NCT03585257 · Cirrhosis, Hepatic Encephalopathy, and more
NCT01966419 · Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Bausch Health Site 18
Corona del Mar, California
Bausch Health Site 15
Los Angeles, California
Bausch Health Site 19
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions